Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. (Q37737382)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

title

Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

main subject

phase II clinical trial

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Jeffrey B Travers

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Mary K. Edwards-Brown

15

object named as

Mary K Edwards-Brown

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Kent A Robertson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Feng-Chun Yang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Daniel C Bowers

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Chang Y Ho

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Gary D Hutchins

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

James M Croop

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Terry A Vik

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Scott C Denne

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Luis F Parada

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Cynthia M Hingtgen

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Laurence E Walsh

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Menggang Yu

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Kamnesh R Pradhan

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Mervyn D Cohen

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

James W Fletcher

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Karl W Staser

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Melissa W Lee

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Marcie R Sherman

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Cynthia J Davis

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Lucy C Miller

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

David A Ingram

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

D Wade Clapp

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

publication date

23 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

1218-1224

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

Phase I trial of pegylated interferon-alpha-2b in young patients with plexiform neurofibromas

16 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Plexiform neurofibroma genesis: questions of Nf1 gene dose and hyperactive mast cells

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Mast cells and the neurofibroma microenvironment

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Neurofibromatosis type 1 revisited

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Tumor microenvironment and neurofibromatosis type I: connecting the GAPs

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Neurofibromas in NF1: Schwann cell origin and role of tumor environment

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Mouse tumor model for neurofibromatosis type 1

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

The measurement of performance in childhood cancer patients

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Nf1+/- mice have increased neointima formation via hyperactivation of a Gleevec sensitive molecular pathway

22 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Interobserver reproducibility of volumetric MR imaging measurements of plexiform neurofibromas.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5380388

Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas

1 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23099009

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: a 1-year follow-up study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23099009

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Karnofsky performance status revisited: reliability, validity, and guidelines

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23099009

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/S1470-2045(12)70414-X

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23099009%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference